Estrogen stimulation of cell migration involves multiple signaling pathway interactions

Endocrinology

Volumn 151, Issue 11, 2010, Pages 5146-5156

  Li, Yan ^a,b   Wang, Ji Ping ^a   Santen, Richard J ^a   Kim, Tae Hyun ^a,c   Park, Hoyong ^a   Fan, Ping ^a   Yue, Wei ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOESIN; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE P60; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; METASTASIS; MOLECULAR INTERACTION; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL CULTURE; CELL MOTION; DRUG EFFECT; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; ESTRADIOL; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENES, SRC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PAXILLIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 78049500936     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1506     Document Type: Article

References (44)

1. Santen RJ, Manni A, Harvey H, Redmond C 1990 Endocrine treatment of breast cancer in women. Endocr Rev 11:221-265
2. Cowin P, Welch DR 2007 Breast cancer progression: controversies and consensus in the molecular mechanisms of metastasis and EMT. J Mammary Gland Biol Neoplasia 12:99-102
3. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T 2005 Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5:744-749
4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA 2008 The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715
5. Welch DR, Cooper CR, Hurst DR, Lynch CC, Martin MD, Vaidya KS, VanSaun MN, Mastro AM 2008 Metastasis research society - American association for cancer research joint conference on metastasis. Cancer Res 68:9578-9582
6. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ 2002 Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol Endocrinol 16:116-127
7. Parsons JT 2003 Focal adhesion kinase: the first ten years. J Cell Sci 116:8-16
8. Friedl P, Wolf K 2003 Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362-374
9. Deakin NO, Turner CE 2008 Paxillin comes of age. J Cell Sci 121:15-44
10. Golubovskaya V, Beviglia L, Xu LH, Earp 3rd HS, Craven R, Cance W 2002 Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 277:38978-38987
11. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, Krishna UM, Falck JR, White MA, Broek D 1998 Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279:558-560
12. Tachibana M, Kiyokawa E, Hara S, Iemura S, Natsume T, Manabe T, Matsuda M 2009 Ankyrin repeat domain 28 (ANKRD28), a novel binding partner of DOCK180, promotes cell migration by regulating focal adhesion formation. Exp Cell Res 315:863-876
13. Li S, Hua ZC 2008 FAK expression regulation and therapeutic potential. Adv Cancer Res 101:45-61
14. Bernards A 2003 GAPs galore!Asurvey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 1603:47-82
15. Bernards R 2003 Cancer: cues for migration. Nature 425:247-248
16. Eswaran J, Soundararajan M, Kumar R, Knapp S 2008 UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci 33:394-403
17. Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, Bouton AH 2007 Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res 67:6174-6182
18. Feigin ME, Muthuswamy SK 2009 ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res 315:707-716
19. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R 2004 p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep 5:154-160
20. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF 2004 FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 6:154-161
21. Simoncini T, Scorticati C, Mannella P, Fadiel A, Giretti MS, Fu XD, Baldacci C, Garibaldi S, Caruso A, Fornari L, Naftolin F, Genazzani AR 2006 Estrogen receptor α interacts with Gα13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 20:1756-1771
22. Song RX, Santen RJ 2006 Membrane initiated estrogen signaling in breast cancer. Biol Reprod 75:9-16
23. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ 2007 Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148:4091-4101 (Pubitemid 47105855)
24. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T 2008 Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3:e2238
25. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A 2009 History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30:343-375
26. Buzdar AU, Coombes RC, Goss PE, Winer EP 2008 Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700-709
27. Jordan VC, Brodie AM 2007 Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72:7-25
28. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA, Katzenellenbogen BS 2008 Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 22:2116-2127
29. Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX 2005 Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 94:213-223 (Pubitemid 41677626)
30. Turner CE 2000 Paxillin and focal adhesion signalling. Nat Cell Biol 2:E231-E236
31. Brown MC, Turner CE 2004 Paxillin: adapting to change. Physiol Rev 84:1315-1339
32. Bellis SL, Miller JT, Turner CE 1995 Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem 270:17437-17441
33. Petit V, Boyer B, Lentz D, Turner CE, Thiery JP, Vallés AM 2000 Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 148:957-970
34. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M 2000 Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 14:999-1009
35. Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, Garcia M 1998 Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Mol Biol 65:163-168
36. Sisci D, Aquila S, Middea E, Gentile M, Maggiolini M, Mastroianni F, Montanaro D, Andò S 2004 Fibronectin and type IV collagen activate ERα AF-1 by c-Src pathway: effect on breast cancer cell motility. Oncogene 23:8920-8930
37. Planas-Silva MD, Waltz PK 2007 Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid BiochemMol Biol 104:11-21
38. Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T 2008 Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 3:e2790
39. Acconcia F, Barnes CJ, Kumar R 2006 Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147:1203-1212
40. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, Agyin JK, Brann D, Sun LZ, Yeh IT, Lee FY, Tekmal RR, Kumar R, Vadlamudi RK 2010 Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res 70:4092-4101
41. Fu XD, Flamini M, Sanchez AM, Goglia L, Giretti MS, Genazzani AR, Simoncini T 2008 Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod 14:225-234
42. Giretti MS, Simoncini T 2008 Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton. Steroids 73:895-900
43. Song RX, Zhang Z, Santen RJ 2005 Estrogen rapid action via protein complex formation involving ERα and Src. Trends Endocrinol Metab 16:347-353
44. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith WA, Hidalgo M 2009 Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 15:4138-4146 ff